+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-01-27Number of Pages: 83

Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

 
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models
 
Chapter 2 Executive Summary
2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
 
Chapter 3 U.S. Vaccine Market Overview
3.1 Introduction
3.2 Vaccine Approval Regulatory Pathway
      3.2.1 Major Steps: Vaccine Development and Commercialization
3.3 Drivers
      3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination
      3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S.
      3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines
      3.3.4 Education and awareness through various governmental and non-profit organizations
3.4 Restraints
      3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development
      3.4.2 High cost associated with vaccine transportation, storage and handling
3.5 Opportunities
      3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases
      3.5.2 The U.S. offers immense potential for adult vaccines market
3.6 Competitive Landscape
      3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
      3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
 
Chapter 4 U.S. Human Vaccine Market Revenue
4.1 Overview
      4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
      4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
      4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
      4.1.4 Hepatitis
              4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.5 Influenza
              4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.6 Meningococcal 
              4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.7 Pneumococcal
              4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.8 Human Papillomavirus (HPV)
              4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.9 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
              4.1.9.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.10 Others
               4.1.10.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
4.2 Pricing Analysis
      4.2.1 Pricing Analysis: Hepatitis Vaccines
      4.2.2 Pricing Analysis: Influenza Vaccines
      4.2.3 Pricing Analysis: Meningococcal Vaccines
      4.2.4 Pricing Analysis: Pneumococcal Vaccines
      4.2.5 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
      4.2.6 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
      4.2.7 Pricing Analysis: Other Vaccines
 
Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million)
5.1 Overview
      5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
5.2 Companion Animal Vaccines
      5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.2.2 Canine Vaccines
              5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.2.2 Pricing Analysis: Canine Vaccines
      5.2.3 Feline Vaccines
              5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.3.2 Pricing Analysis: Feline Vaccines
5.3 Livestock Vaccines
      5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.3.2 Porcine Vaccines
              5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.2.2 Pricing Analysis: Porcine Vaccines
      5.3.3 Bovine Vaccines
              5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.3.2 Pricing Analysis: Bovine Vaccines
      5.3.4 Ovine Vaccines
              5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.4.2 Pricing Analysis: Ovine Vaccines
      5.3.5 Poultry Vaccines
              5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.6 Equine Vaccines
              5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.6.2 Pricing Analysis: Equine Vaccines
 
Chapter 6 Recommendations
6.1 Focus on cost-effective vaccine manufacturing
6.2 Focus on developing technologically advanced vaccines such as DNA vaccines
 
Chapter 7 Company Profiles
7.1 Boehringer Ingelheim
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 GlaxoSmithKline plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Merck & Co., Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Novartis International AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Pfizer, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Sanofi SA
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Zoetis, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments

List of Figures
 
FIG. 1 U.S. Vaccine: Market Segmentation
FIG. 2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
FIG. 3 Major Steps: Vaccine Development and Commercialization
FIG. 4 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 5 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 6 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
FIG. 7 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
FIG. 15 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Boehringer Ingelheim Vetmedica: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 23 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 25 Novartis International AG: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 26 Pfizer, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 27 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 28 Zoetis, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)

List of Tables
 
TABLE 1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
TABLE 2 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
TABLE 3 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
TABLE 4 Pricing Analysis: Hepatitis Vaccines
TABLE 5 Pricing Analysis: Influenza Vaccines
TABLE 6 Pricing Analysis: Meningococcal Vaccines
TABLE 7 Pricing Analysis: Pneumococcal Vaccines
TABLE 8 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
TABLE 9 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
TABLE 10 Pricing Analysis: Other Vaccines
TABLE 11 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
TABLE 12 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 13 Pricing Analysis: Canine Vaccines
TABLE 14 Pricing Analysis: Feline Vaccines
TABLE 15 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 16 Pricing Analysis: Porcine Vaccines
TABLE 17 Pricing Analysis: Bovine Vaccines
TABLE 18 Pricing Analysis: Ovine Vaccines
TABLE 19 Pricing Analysis: Equine Vaccines
TABLE 20 Boehringer Ingelheim: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 21 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 23 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 24 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 25 Sanofi SA: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 26 Zoetis, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)


 
 
Back To Top